Secreted protein acidic and rich in cysteine (SPARC) is an extracellular glycoprotein expressed in several solid cancers, including malignant gliomas, upon adoption of metastatic or invasive behaviors. SPARC expression in glioma cells promotes invasion and survival under stress, the latter process dependent on SPARC activation of AKT. Here we demonstrate that downregulation of SPARC expression with short interfering RNA (siRNA) in glioma cells decreased tumor cell survival and invasion. SPARC siRNA reduced the activating phosphorylation of AKT and two cytoplasmic kinases, focal adhesion kinase (FAK) and integrin-linked kinase (ILK). We determined the contributions of FAK and ILK to SPARC effects using SPARC protein and cell lines engineered to overexpress SPARC. SPARC activated FAK and ILK in glioma cells previously characterized as responsive to SPARC. Downregulation of either FAK or ILK expression inhibited SPARC-mediated AKT phosphorylation, and targeting both FAK and ILK attenuated AKT activation more potently than targeting either FAK or ILK alone. Decreased SPARC-mediated AKT activation correlated with a reduction in SPARC-dependent invasion and survival upon the downregulation of FAK and/or ILK expression. These data further demonstrate the role of SPARC in glioma tumor progression through the activation of intracellular kinases that may provide novel therapeutic targets for advanced cancers.
Introduction
The treatment of patients with primary brain tumors remains one of the greatest challenges in oncology. The median survival of patients with the most aggressive primary brain tumors, World Health Organization grade IV gliomas (glioblastoma multiforme) has reached only 14.6 months in a trial of concurrent chemotherapy and radiotherapy (Stupp et al., 2005) . This high mortality is partially attributable to local invasion of tumor into normal brain, preventing complete surgical resection (Giese et al., 2003) . Although relatively little is known about the molecular events underlying glioma invasion, one implicated protein is secreted protein, acidic and rich in cysteine (SPARC/osteonectin/BM-40). SPARC is an extracellular glycoprotein abnormally expressed in many solid tumors, and SPARC expression can be further elevated upon conversion to invasive and metastatic tumors (Framson and Sage, 2004) . SPARC is overexpressed in astrocytomas of all grades, but is preferentially expressed at sites of tumor invasion (Rempel et al., 1998; Lal et al., 1999) . As SPARC is expressed at low levels in normal adult brain (Mundlos et al., 1992) , but highly expressed in gliomas, SPARC is an attractive target in brain tumor therapy. Increased SPARC expression levels have been linked to poor glioma patient survival (Rich et al., 2005) , which suggests that the reduction of SPARC expression may have therapeutic benefit. Indeed, expression of antisense oligonucleotides against SPARC in melanoma cells blocked tumor formation (Ledda et al., 1997) .
The precise biological and molecular mechanisms through which a reduction in SPARC expression might contribute to improved tumor therapy remain to be investigated. There is no well-established SPARC signal transduction pathway, and SPARC variably affects multiple cell behaviors, including proliferation, apoptosis, angiogenesis and invasion. However, in human glioma cell lines, SPARC increases invasion in vitro and in vivo (Schultz et al., 2002; Rich et al., 2003) . SPARC also promotes cell survival through the activation of AKT/protein kinase B (Shi et al., 2004) , an intracellular serine/threonine kinase known to inhibit apoptosis and known to be activated in cancer (Datta et al., 1999) . We recently demonstrated that exogenous SPARC protein induces activating phosphorylation of AKT within minutes in a concentration-dependent manner, and stable overexpression of SPARC also increases AKT phosphorylation (Shi et al., 2004) . Therefore, we hypothesized that, in gliomas, decreasing SPARC expression could reduce AKT phosphorylation to decrease invasion and increase cell death.
We, now, demonstrate that targeting SPARC expression with short interfering RNA (siRNA) decreases cellular survival and invasion, with a concordant decrease in AKT signaling. Further, we demonstrate that SPARC-mediated AKT phosphorylation involves two cytoplasmic non-receptor tyrosine kinases: focal adhesion kinase (FAK) and integrin-linked kinase (ILK). SPARC activates FAK and ILK, and targeting FAK and/or ILK expression with siRNA reduces AKT phosphorylation and the ability of SPARC to promote invasion and survival. Therefore, our studies establish components of a novel signaling pathway through which SPARC regulates pro-tumorigenic cellular behaviors.
Results
siRNA-mediated downregulation of SPARC expression inhibits glioma cell invasion in vitro siRNA represents both a tool to specifically delineate the function of numerous genes and also a potential therapeutic modality. We tested the ability of a customized siRNA pool (Dharmacon, Chicago, IL, USA) to downregulate the expression of SPARC in two well-characterized glioma lines, U373MG and D54MG, which both express SPARC. SPARC siRNA was highly effective in decreasing SPARC expression relative to a non-targeting siRNA control: SPARC expression decreased by 72.5% in D54MG cells and 90.7% in U373MG cells (Figures 1a and 2a , and data not shown).
To determine if SPARC siRNA could reduce protumorigenic cellular behaviors associated with SPARC expression, we first determined the effect of decreased SPARC expression on tumor cell invasion. We measured the capacity of glioma cells to invade through Matrigel, an artificial extracellular matrix, after transfection with a non-targeting control siRNA or SPARC siRNA. Decreased SPARC expression led to the inhibition of invasion by 54% and 49% in D54MG and U373, respectively. In addition, introduction of SPARC siRNA inhibited the invasion of D54MG and U373MG by greater than 50% when compared with two further siRNA controls directed against luciferase and lamin A/C (Supplementary Figure 1) . Thus, SPARC siRNA can decrease glioma invasion in vitro. SPARC siRNA inhibits the survival of glioma cells As our laboratory previously demonstrated that overexpression of SPARC in glioma cell lines promotes survival under serum starvation (Shi et al., 2004) , we investigated whether SPARC siRNA could decrease the survival of glioma cells under this stress. D54MG and U373MG glioma cells transfected with SPARC siRNA survived at decreased rates relative to matched cells transfected with a non-targeting control siRNA ( Figure 2 ). As expected, the decreased survival of the cells transfected with SPARC siRNA was associated with increased rates of apoptosis as measured by the Annexin V assay. Decreasing SPARC expression increased apoptosis by 54% in D54MG and 99% in U373MG (Figure 2c) . Similarly, siRNA directed against SPARC increased the rate of apoptosis in D54MG and U373MG cells when compared with two additional siRNA controls directed against luciferase and lamin A/C (Supplementary Figure 2) . Thus, SPARC siRNA negatively impacts tumor cell behavior through two related biologic processes-invasion and survival.
SPARC siRNA decreases activation of AKT, FAK and ILK intracellular kinases We next sought to define the molecular mechanisms through which SPARC siRNA could alter tumor cell invasion and survival. Our laboratory previously demonstrated that SPARC activates the phosphoinositide-3-kinase-AKT pathway, a key mediator of cellular survival (Shi et al., 2004) . Therefore, we first determined whether SPARC siRNA could alter AKT phosphorylation at key residues reflecting kinase activation. An siRNA-mediated decrease in SPARC expression reduced the activating phosphorylation of AKT at Serine 473 without affecting total AKT levels ( Figure 3a,  Supplementary Figure 3) .
To further elucidate the molecular mechanisms through which SPARC siRNA could reduce AKT phosphorylation, we screened molecular targets linked to glioma invasion and survival that are known to activate AKT. We determined that reducing SPARC expression could influence the mRNA expression of multiple genes involved in invasion and survival ( Table 1 ), but we detected no changes in the phosphorylation states of several growth factor receptors after transfection with SPARC siRNA (data not shown). These data correlated with our prior studies, which demonstrated that exogenous SPARC protein treatment or overexpression of SPARC in glioma cell lines did not alter the activation of several growth factor pathways. We rather found that SPARC expression changes correlated with decreased activation of FAK ( , as did the kinase activity of ILK ( Figure 3b ). As phosphorylation-specific antibodies of ILK residues that reflect protein activation are currently unavailable, we measured the impact of SPARC on ILK activity through an ILK kinase assay. ILK protein was immunoprecipitated and assessed for kinase activity on myelin basic protein (MBP) as a substrate. Whereas an IgG control antibody did not select for any kinase activity, immunoprecipitation, using an anti-ILK antibody, identified kinase activity in glioma cells transfected with a non-targeting control siRNA that was absent in matched cells transfected with siRNA targeting SPARC (Figure 3b ). Thus, downregulation of SPARC expression decreases the activity of key intracellular kinases linked to cancer invasion and survival.
SPARC activates the non-receptor tyrosine kinases, FAK and ILK To validate the link between SPARC and the activation of FAK and ILK, we performed the reverse experiments to those targeting SPARC expression: we activated the SPARC pathway either through the addition of exogenous SPARC protein or through genetic modification to increase SPARC expression. Treatment of a glioma cell line responsive to SPARC and D54MG with exogenous SPARC protein rapidly induced the phosphorylation of a key regulatory FAK residue, Y397, within minutes, in time and concentration-dependent manners (Figure 4a and b). The activation of FAK by exogenous SPARC protein is self-limited, with a return to baseline phosphorylation levels by 60 min of incubation. These data demonstrate, for the first time, that FAK is a downstream target of SPARC and that the biological responses mediated by SPARC could be due, at least in part, to the phosphorylation and activation of FAK. Cancer cells and tumor-associated stromal elements produce SPARC to provide cancer cells long-term exposure to SPARC. To mimic these effects, we previously created D54MG glioma cell lines transduced to overexpress SPARC (Rich et al., 2003) . In SPARCoverexpressing D54MG cells, FAK phosphorylation was increased relative to vector control cells (Figure 4c ). Exogenous SPARC protein treatment specifically induced ILK kinase activity in a rapid manner relative to the bovine serum albumin control (Figure 5a ). In concordance with these results and those with FAK detailed above, D54MG cells, engineered to overexpress SPARC, also display a constitutive increase in ILK kinase activity (Figure 5b ). Thus, FAK and ILK are potential components of the SPARC intracellular signaling pathway upstream of AKT.
SPARC-mediated AKT phosphorylation is mediated through FAK and ILK
To define the roles of FAK and ILK in SPARCmediated activation of AKT, we targeted FAK and/or (Figure 6a ). The ILK siRNA transfection was modestly more potent in decreasing ILK expression than the FAK siRNA was in decreasing FAK expression (Figure 6a ). Under serum-starved conditions, the addition of SPARC to D54MG cells, transfected with control siRNA, increased AKT phosphorylation, as previously described by us (Shi et al., 2004) (Figure 6a ). Transfection with ILK siRNA decreased SPARC induction of AKT phosphorylation by 67%, whereas transfection with FAK siRNA reduced SPARC-induced AKT phosphorylation by 24% (Figure 6a and data not shown). These results suggest that both FAK and, perhaps more significantly, ILK are downstream of SPARC but upstream of AKT in a signal transduction pathway. The greater effects of targeting ILK expression on SPARC activation of AKT may be due to the greater knockdown efficiency of ILK expression and/or a more direct regulation of AKT activity by ILK. FAK and ILK activation of AKT appears to be additive, as the combined targeting of both FAK and ILK signaling dramatically blocks SPARC activation of AKT phosphorylation by 93% (Figure 6b and data not shown). These results confirm the roles of FAK and ILK in mediating SPARC activation of AKT phosphorylation. Abbreviation: SPARC, secreted protein acidic and rich in cysteine. Total RNA was extracted from 10 7 U373MG or D54MG cells transfected with siRNA directed against SPARC or non-targeting siRNA. Genes similarly regulated by loss of SPARC expression between the two glioma lines are displayed. Spotted array studies were completed at the Duke University Microarray Facility. (a) Exogenous SPARC treatment induces ILK kinase activity. D54MG cells were cultured in 10% serum until 60-75% confluent and then serumstarved overnight. ILK activity was measured over a time course after incubation with a final concentration of 2 mg/ml (46 nM) of human platelet SPARC. ILK kinase assays were performed using a rabbit immunoaffinity-purified ILK antibody and MBP as a substrate. (b) Serum-starved D54MG glioma cell lines expressing SPARC display increased ILK kinase activity. Glioma cell lines, transduced with a control retroviral vector (VEC) or a retrovirus encoding SPARC (SP), were plated in 10% serum overnight, serum-starved overnight and lysed. ILK kinase activity assays were performed as in (a).
there are differential functions of ILK and FAK in mediating survival and invasion. Thus, SPARC requires ILK and FAK expression to contribute to the tumor biology associated with SPARC expression.
Discussion
Infiltrative glioma cells are a particular therapeutic challenge owing to their diffuse localization, distance from the initial site of resection, protection by an intact blood-brain barrier (Kenney et al., 1992) and low frequency of mitosis (Chicoine and Silbergeld, 1995) . The targeting of these invasive glioma cells remains elusive because of a deficiency in our understanding of the molecular events underlying tumor invasion. We now demonstrate the involvement of a novel signal transduction pathway involving SPARC, FAK, ILK and AKT in the control of glioma cell invasion and survival. As elevated SPARC expression is associated with decreased glioma patient survival (Rich et al., 2005) , we believe that our results, demonstrating decreased invasion and increased cell death with siRNA directed against SPARC, suggest that decreasing SPARC expression may have therapeutic benefit for glioma patients. However, as SPARC has the potential to function both as a tumor promoter and tumor suppressor, decreasing SPARC expression may not be beneficial for all tumor types or stages. For example, SPARC induces apoptosis in ovarian cancer cells (Yiu et al., 2001) and inhibits proliferation and metastasis of breast cancer cells (Koblinski et al., 2005) , but breast tumor expression of SPARC is linked to increased patient metastases and poor patient survival (Jones et al., 2004; Watkins et al., 2005) . When we overexpressed SPARC in HeLa cells or a genetically engineered human breast cancer model (HMEC), SPARC-expressing cells suffered a dramatic inhibition of tumor formation when implanted into immunocompromised rodents (data not shown). Of note, treatment with exogenous SPARC protein or overexpression failed to activate AKT in HeLa or HMEC cells (data not shown). These cell-specific results further suggest that SPARC-induced phosphorylation and activation of AKT contribute to tumor promotion.
We have now determined that the phosphorylation of AKT by SPARC involves the activation of two intracellular tyrosine kinases, FAK and ILK, which have been previously implicated in the control of glioma invasion (Troussard et al., 2000; Hecker et al., 2002; Obara et al., 2004; Xie et al., 2004) . Although the precise mechanism through which SPARC activates FAK and ILK remains to be determined, and will be investigated further, we have detected a novel activation of FAK by both exogenous SPARC treatment and stable SPARC expression. In addition, exogenous SPARC and SPARC overexpression increased the kinase activity associated with ILK. SPARC-mediated activation of FAK and ILK is important to SPARC signaling, as siRNA targeting FAK and ILK inhibited the activation of AKT. Furthermore, FAK and ILK activation contribute to SPARC phenotypic effects, as SPARC-mediated glioma cell invasion and survival were blocked through inhibition of FAK and/or ILK expression. Although a recent study showed that SPARC regulates ILK-related activities in fibroblasts (Barker et al., 2005) , our results are the first to demonstrate that ILK activity mediates oncogenic effects of SPARC. The requirement of ILK and FAK activation by SPARC for SPARC-mediated changes in cellular behavior suggests that the expression of some invasive and/or survival genes, disregulated with decreased SPARC expression, may depend upon ILK and/or FAK for transcriptional regulation, and we continue to explore this possibility in studies beyond the scope of this investigation.
Our demonstration of a novel signal transduction pathway involving SPARC, FAK, ILK and AKT, in the control of glioma cell invasion and survival, has additional therapeutic importance, as low-molecularweight inhibitors of the kinase activities of FAK, ILK and AKT are each in preclinical or early clinical development. Our results suggest that tumors expressing SPARC may display particular sensitivity to the antitumor effects of these inhibitors. Thus, SPARC expression levels may permit pre-selection or stratification of patients in clinical trials of these agents. For example, tumor SPARC expression levels in breast cancers have provided markers of sensitivity to an albumin-bound paclitaxel (Gradishar, 2006) , potentially because of SPARC binding of albumin, or another molecular mechanism. In addition, FAK, ILK and AKT inhibitors may display combinatorial efficacy owing to the joint activities of these kinases in tumor cells expressing SPARC. Finally, targeting SPARC expression has already been demonstrated to be useful in the control of melanomas (Ledda et al., 1997; Alvarez et al., 2005) , which further suggests that decreasing SPARC expression in some other cancer types, such as gliomas, may be beneficial for patient therapy.
Materials and methods
Cell lines and culture D54MG is the Duke University subline of A-172. U373MG was purchased from the American Type Culture Collection (Manassas, VA, USA). Vector control or SPARC-overexpressing D54MG cells were created as previously described (Rich et al., 2003) . Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA, USA) media with 10% fetal bovine serum (FBS, Invitrogen) and L-glutamine.
Reagents
Human platelet osteonectin (SPARC) and bovine osteonectin (SPARC) were purchased from Haematologic Technologies (Essex Junction, VT, USA). siRNAs (Dharmacon, Chicago, IL, USA) were used as per the manufacturer's instructions with control non-targeting siRNA (CTRL). Unless otherwise noted, all chemicals were purchased from Sigma (St Louis, MO, USA).
Transfection of siRNA 150 000 cells were plated per six-well in DMEM with 10% FBS and were allowed to attach overnight. Equimolar amounts of siRNAs were incubated with TransIT-TKO Transfection Reagent from Mirus (Madison, WI, USA) as per the manufacturer's instructions. Cells were maintained for 48 h before experiments, unless otherwise described. 
Western analysis
Westerns were completed as previously described (Shi et al., 2004) . Membranes were probed with antibodies against phospho-specific AKT (Ser 473), total AKT (Cell Signaling Technology, Beverly, MA, USA), phospho-specific FAK (Tyr 397) (BioSource, Carlsbad, CA, USA), MBP (Thr 98), total FAK, ILK (Upstate), osteonectin/SPARC (Haematologic Technologies, Essex Junction, VT, USA) and a-tubulin (Sigma). Expression levels were measured using the gel analyser option on ImageJ software (http://rsb.info.nih.gov/ij).
Annexin V assays
Annexin V and propidium iodide staining was completed as previously described (Shi et al., 2004) . In vitro matrigel invasion assay Boyden chamber assays were completed as previously described (Rich et al., 2003) .
Non-radioactive ILK assay

Spotted array experiments
Total RNA was extracted from 10 7 D54MG and U373MG cells transfected with siRNA directed against SPARC or a non-targeting control siRNA using a QIAGEN RNeasy Kit (Qiagen Inc., Valencia, CA, USA). MicroArray experiments were performed at the Duke University Microarray Facility using the human Operon V3.0 array (Operon, Biotechnologies Inc., Huntsville, AL, USA) on a GeneMachine OmniGrid Microarrayer (GeneMachines, San Carlos, CA, USA). Data were analysed using GeneSpringGX software (Agilent Technologies, Palo Alto, CA, USA).
Statistical analysis
Quantitative data are presented as mean7s.d. Significance was assessed by two-tailed Student's t-test for two-way analyses. Analysis of variance was used for multiple comparisons.
